Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 Pipeline Review, H2 2017 [Report Updated: 25072017] Prices from USD $3500
Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 Pipeline Review, H2 2017
Summary
Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Macrophage Stimulating Protein Receptor Pipeline Review, H2 2017, outlays comprehensive information on the Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 Macrophagestimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3kinase subunit PIK3R1, PLCG1. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 2 respectively. Report covers products from therapy areas Oncology and Metabolic Disorders which include indications Gastric Cancer, Breast Cancer, Anaplastic Large Cell Lymphoma ALCL, Anaplastic Thyroid Cancer, Bile Duct Cancer Cholangiocarcinoma, Clear Cell Squamous Cell Carcinoma, Colon Cancer, Glioblastoma Multiforme GBM, Hepatocellular Carcinoma, Lung Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Transitional Urothelial Tract Cancer, Multiple Myeloma Kahler Disease, Neuroblastoma, Osteoporosis, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Rhabdomyosarcoma and Uveal Melanoma.
Furthermore, this report also reviews key players involved in Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1
The report reviews Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
